UBS Group’s BioTime Inc Warrants (Expiring October 1, 2018) BTX.WS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-9,294
| Closed | -$1K | – | 8533 |
|
|
2018
Q2 | $1K | Sell |
9,294
-2,908
| -24% | -$216 | ﹤0.01% | 7910 |
|
|
2018
Q1 | $1K | Buy |
12,202
+10,181
| +504% | +$1.49K | ﹤0.01% | 7732 |
|
|
2017
Q4 | $0 | Sell |
2,021
-680
| -25% | -$121 | ﹤0.01% | 8321 |
|
|
2017
Q3 | $0 | Sell |
2,701
-4,733
| -64% | -$1.14K | ﹤0.01% | 8226 |
|
|
2017
Q2 | $2K | Buy |
7,434
+2,386
| +47% | +$1.02K | ﹤0.01% | 7438 |
|
|
2017
Q1 | $3K | Buy |
5,048
+3,112
| +161% | +$1.77K | ﹤0.01% | 7239 |
|
|
2016
Q4 | $1K | Sell |
1,936
-9,943
| -84% | -$6.76K | ﹤0.01% | 7690 |
|
|
2016
Q3 | $10K | Buy |
11,879
+10,754
| +956% | +$5.39K | ﹤0.01% | 6812 |
|
|
2016
Q2 | $0 | Sell |
1,125
-1,231
| -52% | -$670 | ﹤0.01% | 8160 |
|
|
2016
Q1 | $1K | Buy |
2,356
+1,785
| +313% | +$1.21K | ﹤0.01% | 7510 |
|
|
2015
Q4 | $0 | Sell |
571
-3,763
| -87% | -$3.83K | ﹤0.01% | 8735 |
|
|
2015
Q3 | $3K | Sell |
4,334
-5,989
| -58% | -$5.42K | ﹤0.01% | 7992 |
|
|
2015
Q2 | $11K | Buy |
10,323
+5,503
| +114% | +$10.6K | ﹤0.01% | 7419 |
|
|
2015
Q1 | $10K | Buy |
4,820
+722
| +18% | +$968 | ﹤0.01% | 7663 |
|
|
2014
Q4 | $5K | Buy |
+4,098
| New | +$4.44K | ﹤0.01% | 9035 |
|
UBS Group's BTX.WS Position: Q3 2018 in Review
UBS Group sold out of BioTime Inc Warrants (Expiring October 1, 2018) (BTX.WS) in Q3 2018, closing a stake of 9,294 shares — an estimated $1K sold.
UBS Group first reported a position in BTX.WS in Q4 2014 and held it in 15 quarters. The position peaked at $11K in Q2 2015. 7 funds tracked by Wall St. Rank hold BTX.WS as of Q3 2018.
- UBS Group reported no remaining BioTime Inc Warrants (Expiring October 1, 2018) position as of Q3 2018 after selling out during the quarter.
- UBS Group sold 9,294 BioTime Inc Warrants (Expiring October 1, 2018) shares in Q3 2018, an estimated $1K.
- UBS Group first reported a position in BioTime Inc Warrants (Expiring October 1, 2018) in Q4 2014 and held it in 15 quarters.
- UBS Group's BioTime Inc Warrants (Expiring October 1, 2018) position peaked at $11K in Q2 2015.
- 7 funds tracked by Wall St. Rank held BioTime Inc Warrants (Expiring October 1, 2018) as of Q3 2018.
Based on UBS Group's 13F filing for Q3 2018, filed 14 Nov 2018.